B. Shields

First name
B.
Middle name
M.
Last name
Shields
Hopkins, R., Young, K. G., Thomas, N. J., Godwin, J., Raja, D., Mateen, B. A., et al. (2024). Risk factor associations for severe COVID-19, influenza and pneumonia in people with diabetes to inform future pandemic preparations: UK population-based cohort study. Bmj Open, 14, e078135. http://doi.org/10.1136/bmjopen-2023-078135
Venkatasubramaniam, A., Mateen, B. A., Shields, B. M., Hattersley, A. T., Jones, A. G., Vollmer, S. J., & Dennis, J. M. (2023). Comparison of causal forest and regression-based approaches to evaluate treatment effect heterogeneity: an application for type 2 diabetes precision medicine. Bmc Med Inform Decis Mak, 23, 110. http://doi.org/10.1186/s12911-023-02207-2
Dennis, J. M., Young, K. G., McGovern, A. P., Mateen, B. A., Vollmer, S. J., Simpson, M. D., et al. (2022). Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study. Lancet Digit Health, 4, e873-e883. http://doi.org/10.1016/s2589-7500(22)00174-1
Rodgers, L. R., Weedon, M. N., Henley, W. E., Hattersley, A. T., & Shields, B. M. (2017). Cohort profile for the MASTERMIND study: using the Clinical Practice Research Datalink (CPRD) to investigate stratification of response to treatment in patients with type 2 diabetes. BMJ Open. http://doi.org/10.1136/bmjopen-2017-017989
Dennis, J. M., Henley, W. E., Weedon, M. N., Lonergan, M., Rodgers, L. R., Jones, A. G., et al. (2018). Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data. Diabetes Care. http://doi.org/10.2337/dc18-0344
Curtis, H. J., Dennis, J. M., Shields, B. M., Walker, A. J., Bacon, S., Hattersley, A. T., et al. (2018). Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017. Diabetes Obes Metab. http://doi.org/10.1111/dom.13346
Dennis, J. M., Shields, B. M., Hill, A. V., Knight, B. A., McDonald, T. J., Rodgers, L. R., et al. (2018). Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. Diabetes Care. http://doi.org/10.2337/dc17-1827
Dennis, J. M., Henley, W. E., McGovern, A. P., Farmer, A. J., Sattar, N., Holman, R. R., et al. (2019). Time trends in prescribing of type 2 diabetes drugs, glycemic response and risk factors: a retrospective analysis of primary care data, 2010-2017. Diabetes Obes Metab. http://doi.org/10.1111/dom.13687
McGovern, A. P., Dennis, J. M., Shields, B. M., Hattersley, A. T., Pearson, E. R., & Jones, A. G. (2019). What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study. BMC Med. http://doi.org/10.1186/s12916-019-1307-8
Shields, B. M., Hattersley, A. T., & Farmer, A. J. (2019). Identifying routine clinical predictors of non-adherence to second line therapies in Type 2 diabetes: a retrospective cohort analysis in a large primary care database. Diabetes Obes Metab. http://doi.org/10.1111/dom.13865